Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03706365 · ClinicalTrials.gov registry record · Phase 2

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 2
Development phase
393
Enrollment target
20
Study locations

NCT03706365 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 393 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03706365, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
393 participants
Enrollment target
20
Study locations

Study Summary

This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Placebo
  • DRUG Abemaciclib
  • DRUG Prednisone
  • DRUG Abiraterone acetate

Study Locations (20)

California

  • CBCC Global Research, Inc. - Bakersfield
  • Providence St. Jude Medical Center - Fullerton
  • Moores Cancer Center - La Jolla
  • TRIO-US (Translational Research in Oncology-US) - Los Angeles
  • UCLA Hematology/Oncology - Westwood (Building 100) - Los Angeles
  • Pacific Cancer Care - Monterey
  • Sansum Clinic_Kendle - Santa Barbara

Arizona

  • St. Joseph's Hospital and Medical Center - Phoenix
  • Mayo Clinic in Arizona - Phoenix - Phoenix
  • The University of Arizona Cancer Center - North Campus - Tucson

New York

  • New York Oncology Hematology (NYOH) - Clifton Park Cancer Center - Albany
  • Associated Medical Professionals - Urology - Syracuse

Arkansas

  • St. Bernards Medical Center - Jonesboro

Colorado

  • Rocky Mountain Cancer Center - Lone Tree

Florida

  • Millennium Oncology - Hollywood - Hollywood

Georgia

  • Northside Hospital - Atlanta

Indiana

  • Fort Wayne Medical Oncology And Hematology at Parkview Comprehensive Cancer Center - Fort Wayne

Trial Details

FieldValue
Enrollment Target 393 participants
Start Date 2018-11-26
Est. Completion 2026-06
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03706365

The ClinicalTrials.gov registry entry for NCT03706365 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (35% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT03706365 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Arizona, New York.

Frequently Asked Questions

What is clinical trial NCT03706365 about?

NCT03706365 is a clinical study titled "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer". This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

What is the current status of trial NCT03706365?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 393 participants. The study started on 2018-11-26. Estimated completion is 2026-06.

What conditions does trial NCT03706365 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03706365?

The interventions under investigation include: Placebo (DRUG), Abemaciclib (DRUG), Prednisone (DRUG), Abiraterone acetate (DRUG).

Who is sponsoring clinical trial NCT03706365?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03706365 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.